Guide
Structure/Function Claims Readiness: The DSHEA Boundary, FTC Substantiation and the Disease-Claim Line for Dietary Supplements
A structure/function claim is the workhorse marketing claim of the US dietary supplement industry — 'supports immune function', 'helps maintain healthy cholesterol levels', 'promotes joint comfort'. The legal basis is the Dietary Supplement Health and Education Act 1994 (DSHEA), which under section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act permits supplements to describe the role of a nutrient or dietary ingredient in affecting the structure or function of the human body, provided the claim is truthful, not misleading, and accompanied by the mandatory disclaimer. The line between a permitted structure/function claim and a prohibited disease claim is the most consequential regulatory boundary in the US supplement market. Cross it and the product becomes an unapproved new drug subject to immediate FDA enforcement; observe it and substantiate it well, and the claim runs. This guide maps the rules and the operating posture that keeps claims on the right side of the line.
Start free trial Free trial, no credit card, onboard in days, not months.
What DSHEA 403(r)(6) actually permits — and what the disclaimer must say
Section 403(r)(6) permits a dietary supplement to bear a statement that describes the role of a nutrient or dietary ingredient intended to affect the structure or function of the human body, characterises the documented mechanism by which a nutrient or dietary ingredient acts to maintain such structure or function, or describes general well-being. The statute requires four conditions: (1) the manufacturer must have substantiation that the statement is truthful and not misleading; (2) the statement must include the mandatory disclaimer 'This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease' on the label, prominently displayed; (3) the manufacturer must notify the FDA in writing within 30 days of first marketing the claim (FDA Form 3952); (4) the claim must not be a disease claim. The disclaimer is mandatory on every product bearing a structure/function claim — placement, prominence and exact wording are regulated by 21 CFR 101.93.
The disease-claim line — and where supplements cross it
The disease-claim boundary is set by FDA in 21 CFR 101.93(g) and elaborated in the 2002 guidance. A claim is a prohibited disease claim if it expressly or by implication claims to diagnose, mitigate, treat, cure or prevent a specific disease or class of diseases. Express crossings: 'treats arthritis', 'cures insomnia', 'prevents heart disease'. Implied crossings: product names ('Cardio-Cure'), ingredient claims tied to a disease ('contains red yeast rice — lowers cholesterol'), citations to scientific literature studying disease, before-and-after imagery suggesting disease treatment, testimonials describing disease cure, the use of medical terms (osteoarthritis vs joint comfort, hypertension vs healthy blood pressure), and metatags or hidden keywords on a product webpage. FDA enforcement runs from Warning Letters (the most common) to seizure and injunction for repeat offenders. FTC parallel enforcement is separate and frequently more financially damaging.
Substantiation — the FTC standard above the FDA disclaimer
The FDA disclaimer satisfies labelling formalities; substantiation satisfies the law. The Federal Trade Commission, under Section 5 of the FTC Act, requires that any objective product claim be substantiated by 'competent and reliable scientific evidence' — defined in the FTC's 2022 Health Products Compliance Guidance as tests, analyses, research or studies that have been conducted and evaluated in an objective manner by qualified persons, using procedures generally accepted in the relevant scientific field to yield accurate and reliable results. For health claims, the FTC's revised expectation is at least one well-designed human clinical trial on the finished product or the active ingredient at the marketed dose — surrogate evidence (animal models, in vitro assays, traditional use) is generally insufficient. Substantiation must exist at the time the claim is first made, must cover every claim made and every reasonable implication, and must be current as the science evolves.
The 30-day FDA notification — what to file, what FDA does with it
Within 30 days of first marketing a structure/function claim, the manufacturer must notify the FDA Office of Dietary Supplement Programs in writing — typically by submitting FDA Form 3952 (Statement of Nutritional Support Notification) covering the manufacturer name and address, the statement being made, the name of the dietary supplement product (with the Supplement Facts panel), and a certification by the responsible individual that the statement is truthful and not misleading. The FDA logs the notification and does not pre-approve the claim. The notification is public-record. FDA can later challenge the claim through Warning Letter or enforcement action, regardless of notification — notification is not approval, and saying 'we notified FDA' is not a defence. Failure to notify is itself a violation.
An operating posture for compliant claim management
Six-point posture for sustainable structure/function claims. (1) Claim library — a controlled list of approved claim wordings, tied to substantiation files, with disease-term and implied-disease blacklist scanning. (2) Substantiation file per claim — current, dated, with the FTC scientific evidence rating, owned by a named scientific reviewer. (3) Disclaimer enforcement — every label, every product page, every Amazon listing, every marketplace carries the 21 CFR 101.93 disclaimer in correct placement and prominence. (4) FDA 30-day notification — filed within the window, tracked per SKU, refiled when the claim or product changes materially. (5) Marketing copy review — every new piece of promotional copy (web, social, print, video, podcast read, influencer brief) passes through a claim-review step before it goes live. (6) Periodic re-review — substantiation files re-validated annually, with sunset on claims whose evidence has been superseded.
Standards covered in this guide
Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.
Where this lives in V5 Ultimate
The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.
Modules that do the work
Industries this hits hardest
Frequently asked
What is the difference between a structure/function claim and a health claim?
A structure/function claim describes the role of a nutrient on the body's structure or function ('supports immune function'); it requires substantiation, the FDA disclaimer and 30-day notification, but no pre-market FDA approval. A health claim describes a relationship between a substance and a disease or health-related condition ('calcium reduces the risk of osteoporosis'); it requires either FDA pre-approval (Authorised Health Claim) or qualified-health-claim status with specific qualifying language. The two regimes are distinct and have different evidence bars.
Does FDA approve structure/function claims?
No. FDA does not pre-approve structure/function claims. The 30-day notification under 21 CFR 101.93 is informational — FDA receives the claim text, logs it, and can challenge it later through Warning Letter or enforcement. Saying 'this claim was filed with FDA' is not the same as 'this claim was approved by FDA', and the latter would itself be a misleading claim.
How strong does substantiation need to be?
The FTC 'competent and reliable scientific evidence' standard, as elaborated in the 2022 Health Products Compliance Guidance, generally expects at least one well-designed human clinical trial on the finished product or the active ingredient at the marketed dose. Traditional use, animal models, in vitro assays and mechanistic studies are usually insufficient alone for objective efficacy claims. The required strength scales with the specificity of the claim — narrower and more specific claims need stronger substantiation.
What is the biggest risk in structure/function claim management?
Drift across the disease-claim line through implied claims — product naming, ingredient-disease associations on the product page, study citations referring to disease populations, testimonials describing disease cure, hidden metadata. Express disease claims are usually caught at label review; implied claims slip through marketing channels where the regulatory team has less visibility. Multi-channel claim discipline (label + DTC + Amazon + marketplace + influencer + paid social) is the operational hard part.
See it on your shop floor.
Free trial, no credit card, onboard in days, not months.
Related reading
- 10 CFR 35 medical use readiness — NRC licensing for radiopharmaceuticals
- 21 CFR 111 Readiness: Dietary Supplement cGMP Subparts E & F
- 21 CFR 211 Drug cGMP Readiness Guide
- 21 CFR 212 PET drug cGMP readiness — FDA inspection playbook
- 21 CFR 589 BSE / Ruminant Feed Ban Readiness Guide
- 21 CFR 820 to ISO 13485 Mapping Guide (Including QMSR Harmonisation)
Spot something off? .